Branded

LEXINGTON, Mass. — Cubist has completed its purchase of Trius Therapeutics, Cubist said.

The $704 million acquisition will give Cubist control of the drug tedizolid phosphate, an experimental drug that it said had the potential to treat resistant infections. Trius ceased to be traded on the NASDAQ earlier this week.

SILVER SPRING, Md. — Companies that make long-acting opioid painkillers will be required to conduct studies to assess their safety, while use of the drugs will be restricted, under new requirements from the Food and Drug Administration.

The agency announced new labeling changes and regulatory requirements for makers of extended-release and long-acting opioids, citing the risk the drugs carry of overdose, abuse and withdrawal. In response, a group also cautioned consumers to be careful when using non-steroidal anti-inflammatory drugs.

ABBOTT PARK, Ill. — Dow Jones has named Abbott an industry group leader in its 2013 Dow Jones Sustainability Index, Abbott said Thursday.

The drug maker said it achieved the top spot among healthcare companies and was one of only 24 companies selected for leading their respective industries, chosen from among 3,000 companies worldwide.

WOODCLIFF LAKE, N.J. — Drug maker Eisai has launched a new support and savings program for patients using a weight-loss drug that it makes.

The drug maker announced Thursday the availability of Believe Everyday Support for patients using Belviq (lorcaserin hydrochloride), which includes a customizable online portal designed to help patients reach their weight loss goals and sustain their efforts.

NEW YORK — While pertussis is often considered a childhood disease, a new study from GlaxoSmithKline indicates it's a lot more common among older adults than commonly reported.

PRINCETON, N.J. — According to Kantar Media's 2013 pharmacy study released last month, pharmacists are making more OTC product recommendations than prescription product recommendations per day.

WASHINGTON — A vaccine to slow the progression of HIV and a monoclonal antibody that protects against influenza are among the nearly 300 vaccines under development by drug makers in the United States, according to a new report by a drug industry trade group.

NEWARK, Calif. — Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.

The licensing agreement, which the two companies entered in July 2009, gives Merck a non-exclusive license and other rights to certain Depomed patents for extended-release metformin, while Depomed will receive "modest" royalties on net product sales of the drug Janumet XR (sitagliptin; metformin hydrochloride) in countries in which the licensed patents cover the product.